MBX Biosciences, Inc. Common Stock logo

MBX Biosciences, Inc. Common Stock(MBX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$55.94
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MBX

11/13/2026: MBX (1-star) is currently NOT-A-BUY. Pass it for now.

MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for rare endocrine and metabolic disorders. Its primary strength lies in its proprietary PEP platform and late-stage lead candidate canvuparatide, which target high unmet medical needs with convenient dosing profiles. The core investment story centers on pipeline expansion into lucrative obesity and metabolic markets alongside clinical validation. However, the company faces typical biotechnology risks, including pre-revenue financial losses, clinical trial uncertainties, and intense market competition. The stock is best suited for growth-oriented investors willing to tolerate high volatility, with key developments to monitor including upcoming Phase 3 trial data readouts and metabolic pipeline progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveThe company offers high-growth potential tied to clinical pipeline advancement in rare endocrine and metabolic markets.
Momentum investorStrong fit while signal remains positiveStock price movements are heavily influenced by clinical trial readouts and regulatory catalysts.
Value investorWeak fitThe absence of current commercial revenue and earnings makes traditional value metrics inapplicable.
Dividend investorWeak fitThe company does not pay dividends, focusing entirely on clinical pipeline reinvestment.
Low-risk investorWeak fitClinical-stage biotechnology stocks carry high clinical, regulatory, and price volatility risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology shares experience sharp price movements around trial data releases and capital market conditions.
Valuation riskHighValuations rely heavily on long-term clinical assumptions rather than current earnings or cash flows.
Competition risk (rare disease and metabolic therapeutics competition)Medium / highAlternative therapies developed by larger competitors could threaten commercial potential if approved.
Business qualityMediumThe company possesses a promising proprietary drug platform, but lacks commercial-stage assets.
Dividend incomeLow / noneNo dividend is distributed to shareholders.
Execution riskHighSuccess depends entirely on successfully completing complex clinical trials and securing regulatory approvals.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.78B USD
Price to earnings Ratio -
1Y Target Price 95.09
Price to earnings Ratio -
1Y Target Price 95.09
Volume (30-day avg) 572.9K shares
Beta 0.18
52 Weeks Range 24.68 - 72.64
Updated Date 11/15/2026
52 Weeks Range 24.68 - 72.64
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.03

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -33.28%
Avg. Invested days 17
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MBX receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
MBX has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-40.5%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
MBX's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
MBX's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-40.5%, negative) and free-cash-flow growth (-47.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 117.3% and approximately 65.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.22% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Frazier Life Sciences Management, L.P. 13.40%
FMR Inc 10.72%
Wellington Management Company LLP 10.03%
NEA Management Company, LLC 7.28%
Orbimed Advisors LLC 6.91%

Unit Economics (Per $1K Revenue)

★★★★★
MBX generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
MBX has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic DevelopmentInvestigational peptide drug candidates targeting endocrine and metabolic conditions.The company is pre-revenue and relies on future drug approvals or partnerships to generate sales.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2.30B
Price to Sales(TTM) -
Enterprise Value 2.30B
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 49.66M
Shares Floating 32.49M
Shares Outstanding 49.66M
Shares Floating 32.49M
Percent Insiders 3.22
Percent Institutions 117.28

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.